Please login to the form below
Kisplyx
This page shows the latest Kisplyx news and features for those working in and with pharma, biotech and healthcare.
NICE gives green light to Ipsen's Cabometyx
Meanwhile, NICE is in the process of assessing Eisai’s Kisplyx (lenvatinib) - approved by European regulators in 2016 as a second-line combination treatment for advanced RCC, guidance from England’s
Latest news
-
Eisai wins EU licence for kidney cancer drug Kisplyx
Under brand name Lenvima, Kisplyx was granted US marketing authorisation in May this year, the drug having received breakthrough and priority review status by the FDA. ... Analysts are now suggesting that with Kisplyx's approval in two key markets, plus
-
HIV prevention pill heads July CHMP recommendations
Gilead’s Truvada given positive opinion alongside Ipsen Pharma’s Cabometyx and Eisai’s Kisplyx. ... The panel also recommended approval of two targeted kidney cancer medicines - Ipsen Pharma's Cabometyx (cabozantinib) and Eisai's Kisplyx (lenvatinib
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
